Revised IPSS (IPSS-R) stratification and outcome of MDS patients treated with azacitidine

Annals of Hematology

Volumn 92, Issue 3, 2013, Pages 411-412

  Breccia, Massimo ^a   Salaroli, Adriano ^a   Loglisci, Giuseppina ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE;

ADULT; AGED; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GROWTH; CANCER PATIENT; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOMONOCYTIC LEUKEMIA; COHORT ANALYSIS; CYTOGENETICS; DRUG EFFICACY; FEMALE; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LETTER; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; REVISED INTERNATIONAL PROGNOSTIC SCORING SYSTEM; RISK ASSESSMENT; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; AZACITIDINE; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84873997950     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1581-4     Document Type: Letter

References (4)

1. Greenberg P, Cox C, Le Beau MM, Fenaux P, Morel P, Sanz G et al (1997) International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89(6):2079-2088
2. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solè F et al (2012) Revised international prognostic scoring system (IPSS-R) for myelodysplastic syndromes. Blood. doi: 10.1182/blood-2012-03-420489
3. Lamarque M, Raynaud S, Itzykson R, Thepot S, Quesnel B, Dreyfus F, et al. Impact of the provisional revised-IPSS (R-IPSS) in 265 MDS patients treated with azacitidine (AZA): the group Francophone des Myelodysplasies (GFM) experience. Blood 2011; 114: abstract 972
4. Itzykson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P et al (2011) Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood 117(2):403-411